Head and neck squamous cell carcinomas (HNSCC) are the seventh-most prevalent form of cancer and are associated with human ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Researchers discovered that exposing cancer cells to vibration mimicking vocal cord movement reduced their malignancy.

The health condition can cause throat or oropharyngeal cancer in high-risk cases, though many of the symptoms which indicate ...

Detailed price information for Corbus Pharmaceuticals Hldgs Inc (CRBP-Q) from The Globe and Mail including charting and trades.

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Shilpa Biologicals and mAbTree Biologics secure US FDA orphan drug designation for breakthrough biologics to treat rare blood cancers: Our Bureau, Bengaluru Friday, March 13, 2026 ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility Analysis SYDNEY, AUSTRALIA, March 13, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: ...

Tremendous activity in recent months, including receipt of Japanese marketing approval, the fifth parallel U.S. trial approval, data from pancreatic cancer trials presented at ASCO GI Symposium, and ...

Immutep Limited IMMP shares are tumbling on Friday following the company’s update for the TACTI-004 Phase 3 trial. The Australia-based biotech announced that the Independent Data Monitoring Committee ...

An ASX biotech formerly worth over $500 million has lost most of its value after its drug failed to treat lung cancer ...